Company Profile for Inovio Biomedical Corporation.Inovio Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy electroporation therapy Therapeutics A form of drug delivery that generates electrical pulses via an electrode placed in a tumor to enhance the ability of a chemotherapeutic–eg, bleomycin to enter tumor cells involves using electric fields to open pores in . The therapy targets a significant unmet clinical need: the selective killing of cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer and local ablation of solid tumors while preserving healthy tissue. The company is moving its lead product, the MedPulser(R) Electroporation Therapy System, through pre-marketing studies for head and neck cancer and skin cancer in Europe, where it has CE Mark accreditation, and a U.S. Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA pivotal study for recurrent head and neck cancer. Merck, Vical, Chiron, the U.S. Navy, and other partners are employing Inovio's electroporation electroporation (i·lekˈ·trō·p  ·rāˑ·sh technology, which enhances local delivery and cellular
uptake of useful biopharmaceuticals, in their development of novel DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. vaccines and gene therapies. Inovio is a leader in electroporation, with 57 US and 125 corresponding foreign patents, plus numerous pending patents in the US and abroad.
Company: Inovio Biomedical Corporation
Headquarters Address: 11494 Sorrento Valley Road
San Diego, California 92121-1318
Main Telephone: 858-597-6006
Website: www.inovio.com
Ticker: INO(AMEX)
Type of Organization: Public
Industry: Health: Biotechnology
Key Executives: CEO: Avtar Dhillon, MD
CFO: Peter Kies
Investor Relations
Contact: Corporate Communications
Phone: 877-446-6846
Email: investor.relations@inovio.com
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion